Gheuens Sarah sold $914K of AGIO

Gheuens Sarah (Chief Medical Officer) sold 30,000 shares of AGIOS PHARMACEUTICALS, INC. (AGIO) at $30.48 ($0.91M total) on 2026-08-04 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Gheuens Sarah
Published Aug 6, 2026, 4:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 7, 2026, 7:43 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$AGIO
Neutral
high confidence
Mentioned
$AGIO
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$AGIONeutralLow
01

Why it matters

The disclosed event is an open-market sale by the Chief Medical Officer, executed under a pre-arranged Rule 10b5-1 plan, which generally limits inference about near-term fundamentals.

02

Market read

Traders may note insider selling optics, but the 10b5-1 structure and lack of other company-specific catalysts make this low-conviction for price action.

03

What to watch

Insider sales can be misread; without accompanying buy transactions, guidance, trial updates, or enforcement/regulatory actions, the trading signal is weak.

Relevance 4/10Novelty 3/10Timing: Form 4 filed Aug 6, covering a sale executed Aug 4.

Background

The article is an SEC Form 4 insider transaction disclosure for AGIOS PHARMACEUTICALS, Inc.

Company-level read

Ticker impact

$AGIONeutralHigh confidence
Context

AGIOS PHARMACEUTICALS CMO Gheuens Sarah sold 30,000 shares in an open-market transaction valued at $914,400 on Aug 4.

Expected impact

Likely limited near-term impact; any effect would be short-lived unless followed by additional disclosures.

Evidence & confidence

The filing is a Form 4 insider transaction with explicit 10b5-1 pre-arrangement, which typically reduces interpretive weight versus discretionary selling.

Market effects

Minimal; insider sale does not change sector fundamentals or regulatory/clinical expectations from the text provided.

None indicated.

None indicated.

Counterpoint

The sale could be purely liquidity-driven under the pre-arranged 10b5-1 plan and may not reflect any change in company outlook.

Key entities

  • AGIOS PHARMACEUTICALS, INC.

    Subject of the Form 4 insider transaction disclosure.

  • Gheuens Sarah

    Chief Medical Officer who sold 30,000 shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$AGIOMed

Agios Earnings Call: AQVESME Growth Meets FDA Uncertainty

Agios Pharmaceuticals (AGIO) reported Q3 revenue of $55.4M, up from $12.9M a year earlier, driven by strong AQVESME adoption. The company saw 177 new prescriptions, with 75% patient persistence. International revenue rose 74% to $6.6M. Agios prepares for a potential sickle cell launch, but faces FDA review extension and higher expenses. Q3 net loss narrowed to $65M from $103M YoY.

$AGIOMed

Agios Pharmaceuticals Inc (AGIO) (Q3 2026) Earnings Call Highlights: Revenue Surges 4x

Agios Pharmaceuticals (AGIO) reported Q3 2026 revenue surged 4x, but faced a 3-month FDA review delay for mitapivat in sickle cell disease, increasing uncertainty. Net loss narrowed to $65M from $103.4M YoY. Selling expenses rose to $56.5M, and no 2027 guidance was provided. Thalassemia launch growth may moderate, with 177 prescriptions as a new run rate. Pipeline programs remain early-stage.

$AGIOMed

Agios Pharmaceuticals, Inc. Q3 2026 Earnings Call Summary

Agios Pharmaceuticals reported Q3 2026 revenue of $55.4M, driven by mitapivat in thalassemia. The company plans to cut R&D headcount by 35% to focus on rare hematology and aims for non-GAAP profitability in 2028. Mitapivat's sickle cell disease approval was delayed to February 2027 due to FDA review. The company is also advancing AG-236 for polycythemia vera and cevidoplenib for immune thrombocytopenia.

$AGIOMed

Agios (AGIO) Q3 2026 Earnings Call Transcript

Agios (AGIO) reported Q3 2026 earnings, highlighting $55.4M in mitapivat revenue, a 3-month FDA review extension for sickle cell disease, and $907M in cash. The company plans to reduce R&D headcount by 35% and aims for non-GAAP profitability in 2028. Mitapivat saw a 4x revenue increase YoY, with strong U.S. and international demand.

$AGIOHigh

Truist cuts Agios Pharma stock price target on SCD concerns

Truist Securities reduced its price target for Agios Pharmaceuticals (NASDAQ: AGIO) to $35 from $37, citing concerns about sickle cell disease. The stock is currently trading at $28.38, down 15.7% over the past week. Agios reported Q3 2026 earnings that missed expectations, but revenue exceeded estimates. The company announced a 35% reduction in R&D headcount, aiming for non-GAAP profitability in 2028.

$AGIOHigh

Agios Q3 Mitapivat Revenue Surges More Than Fourfold; Sickle Cell FDA Decision Set For February 2027

Agios Pharmaceuticals (AGIO) reported Q3 2026 revenue of $55.4M for mitapivat products, up over fourfold YoY. U.S. revenue rose to $48.7M, while ex-U.S. revenue increased to $6.6M. Net loss narrowed to $65.0M. The FDA extended the PDUFA goal date for mitapivat in sickle cell disease to February 2027. Agios plans to reduce R&D workforce by over 35% by year-end 2026.